Tenatra

Tenatra is a preclinical-stage biotechnology company focused on developing novel therapies that target the Senescence-Associated Secretory Phenotype (SASP) to treat age-related diseases. Founded by renowned aging researchers Judith Campisi and Marco Quarta, the company utilizes a senomorphic approach to modulate the pro-inflammatory secretome of senescent cells rather than eliminating the cells themselves. By neutralizing these harmful signaling factors, Tenatra aims to alleviate chronic inflammation and promote tissue regeneration in various degenerative conditions. The company's technology platform is designed to identify specific SASP components that drive disease progression, enabling the development of targeted small molecule inhibitors. Tenatra eventually transitioned and rebranded as Rubedo Life Sciences to further advance its pipeline of longevity-focused therapeutics.